Literature DB >> 3395535

Pharmacokinetics of midazolam in anaesthetized cirrhotic patients.

J H Trouvin1, R Farinotti, J P Haberer, F Servin, M Chauvin, P Duvaldestin.   

Abstract

The pharmacokinetics of midazolam were compared in cirrhotic patients (n = 10) and control patients (n = 9), during general anaesthesia. Total plasma clearance was 637 +/- 223 ml min-1 (mean +/- SD) in control patients and 402 +/- 170 ml min-1 in cirrhotic patients (P less than 0.05). The total volume of distribution was similar. Elimination half-life was 135 +/- 40 min in controls and 168 +/- 30 min in cirrhosis (P less than 0.05). Protein binding was evaluated by equilibrium dialysis in both groups at two concentrations of midazolam: 20 and 500 micrograms litre-1. No saturation occurred, but the free fraction was 4.9 +/- 1.7% in cirrhotic patients, compared with 1.9 +/- 0.6% in controls (P less than 0.01). Despite its mainly hepatic elimination, midazolam disposition appears to be only slightly impaired in cirrhotic patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3395535     DOI: 10.1093/bja/60.7.762

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  17 in total

Review 1.  Sedation and analgesia in paediatric intensive care units: a guide to drug selection and use.

Authors:  J D Tobias
Journal:  Paediatr Drugs       Date:  1999 Apr-Jun       Impact factor: 3.022

Review 2.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

Review 3.  Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment.

Authors:  Gail D Anderson; Shahin Hakimian
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 6.447

4.  High-Fat Diet Feeding Alters Expression of Hepatic Drug-Metabolizing Enzymes in Mice.

Authors:  Miaoran Ning; Hyunyoung Jeong
Journal:  Drug Metab Dispos       Date:  2017-04-25       Impact factor: 3.922

Review 5.  Effects of liver disease on pharmacokinetics. An update.

Authors:  V Rodighiero
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

6.  A Prediction Model of Drug Exposure in Cirrhotic Patients According to Child-Pugh Classification.

Authors:  Julie Steelandt; Elodie Jean-Bart; Sylvain Goutelle; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2015-12       Impact factor: 6.447

7.  Intestinal first pass metabolism of midazolam in liver cirrhosis --effect of grapefruit juice.

Authors:  Vibeke Andersen; Natalie Pedersen; Niels-Erik Larsen; Jesper Sonne; Steen Larsen
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

8.  Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo.

Authors:  I E Templeton; K E Thummel; E D Kharasch; K L Kunze; C Hoffer; W L Nelson; N Isoherranen
Journal:  Clin Pharmacol Ther       Date:  2007-05-09       Impact factor: 6.875

9.  CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scores.

Authors:  Albader Albarmawi; David Czock; Annika Gauss; Robert Ehehalt; Justo Lorenzo Bermejo; Jürgen Burhenne; Tom M Ganten; Peter Sauer; Walter E Haefeli
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

Review 10.  Pharmacokinetic changes of psychotropic drugs in patients with liver disease: implications for dose adaptation.

Authors:  Chantal Schlatter; Sabin S Egger; Lydia Tchambaz; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.